Dedicated to Research Since 1993
  •  

    info@genesismarketinsights.com

Global Insulin Delivery Devices Market by Type (Pens, Pumps, Pen Needles, Syringes) by End User (Patients/Homecare, Hospitals and clinics) – Business Overview, Analysis and Industry Forecast 2017-2023

 Healthcare and Pharmaceuticals

Report Overview

Global Insulin Delivery Devices Market was valued at USD XX Billion in the year 2017. Global Insulin Delivery Devices Market is further estimated to grow at a CAGR of XX% from 2018 to reach USD XX Billion by the year 2023. The North America region holds the highest market share in 2018 and the Asia Pacific is considered as the fastest growing market in the forecasted period. At a country level, US, China, and the U.S. are projected to grow strongly in the coming years due to increasing density of population and funding through Research and Development.

Becton, Dickinson and Company (U.S), Novo Nordisk A/S (Denmark),Ypsomed Holding AG (Switzerland). Rising research and development expenses are catering to changing demand of end users. Similarly, growth strategies such as acquisition, merger, and expansion of the distribution network were few techniques adopted by most of Tier 1 and Tier 2 manufacturers in recent years. 

Drivers:           

            Growing diabetic population 

            Rising awareness about insulin delivery devices 

Restraints: 

            Lack of reimbursement facilities 

Opportunities: 

            Technological advancement 

Challenges: 

            The high cost associated with R&D

The Global Insulin Delivery Devices Market is segmented as By Type, End User and Region. By Type, the market is segmented into pens, pumps, pen needles, syringes and other devices. On the basis of End User, it is divided into patients/homecare and hospitals and clinics in which the insulin pen segment accounted for the largest market share due to increasing prevalence of type 1 diabetes, rising diabetic healthcare expenditure etc. By End User, the market is segmented into fertility clinics, hospitals and others in which the patients/homecare segment accounted for the largest market share due to increasing diabetic population and rising healthcare expenditure. Among all, it is expected that fertility clinics segment will be growing at a moderate CAGR of XX % in the assessment period. 

Key Benefits for Stakeholders

Manufacturers of pen needles, insulin pens, pumps, syringes, and injectable drug delivery devices

Suppliers and distributors of pen needles, insulin pens, injectable drug delivery devices, and diabetes supplies

Research institutes and academic centers

Pharmaceutical and biopharmaceutical companies

Biotechnology companies

Authorities framing reimbursement policies for insulin delivery devices

Business research and consulting service providers

Venture capitalists

By Type

Pens

Pumps

Pen Needles

Syringes

Other Devices

By End User

Patients/Homecare

Hospitals and clinics

By Region

North America

Europe

Asia-Pacific

RoW

Key Market Players

Becton, Dickinson and Company

Novo Nordisk A/S

Ypsomed Holding AG

Medtronic plc

Animas Corporation

Tandem Diabetes Care, Inc.

Sanofi

Biocon Ltd.

Eli Lilly and Company

Insulet Corporation

 (A brief overview of 10 companies is also provided)

Research Methodology:

Genesis Market Insights follows in-depth Research Methodology focused on reducing deviation in the collected data. GMI offers the most precise evaluations and projection for the market numbers. GMI engages following Market Engineering techniques –

  1.      Raw Market Data is collected and compared with the Existing in-house Data on a broad front.
  2.      Both Bottom-Up and Top-Down approaches are analyzed for segmenting and estimating measurable aspects of the market.
  3.      To avoid bias, we filter the collected data collected from authenticated sources.
  4.      GMI has a well proven Statistical Modeling System for estimates and forecasts.
  5.      Further, the report findings are validated with the Industry Expert Panel on face to face or telephonic interviews.
  6.      Panelists are approached from Leading Enterprises across the value chain including manufacturers, suppliers, technology providers, domain experts and buyers so as to validate a thorough and balanced market overview.

Detailed customization is also available for you. Further, if the report listed above does not meet your key requirements. Our customized research report will analytically cover the required market information you need which will help you to plan your business decisions.

Table Of Content

1. Introduction

1.1 Market Vision

       1.1.1 Market Definition

       1.1.2 Market Scope

1.2 Limitations

1.3 Stakeholders

2. Research Methodology

2.1. Research Process

       2.1.1. Secondary Research

             2.1.1.1. Key Data from Secondary Research

       2.1.2. Primary Research

             2.1.2.1. Key Data from Primary Research

             2.1.2.2. Breakdowns of Primary Interviews

2.2. Market Size Estimation

       2.2.1. Bottom-Up Approach

       2.2.2. Top-Down Approach

       2.2.3. Annual Revenue Process

2.3. Data Triangulation 

2.4. Research Assumptions 

       2.4.1. Assumption

3. Executive Summary

4. Market Overview

4.1. Introduction

4.2. Drivers

4.3. Restraints

4.4. Opportunities

4.5. Challenges

4.6. Regulations

4.8. Supply Chain/Value Chain Analysis

4.10. Patent & Standards

5. Industry Trends

5.1. Introduction

5.2. Porter’s Five Forces Analysis

       5.2.1. Threat of New Entrants

       5.2.2. Threat of Substitutes

       5.2.3. Bargaining Power of Buyers

       5.2.4. Bargaining Power of Suppliers

       5.2.5. Intensity of Competitive Rivalry

6. Insulin Delivery Devices Market, By Type

6.1 Pens

            6.1.1 Reusable Pens

            6.1.2 Disposable Pens

6.2 Pumps

            6.2.1 External/Tethered Pumps

            6.2.2 Patch Pumps

6.3 Pen Needles

            6.3.1 Standard Pen Needles

            6.3.2 Safety Pen Needles

6.4 Syringes

6.5 Other Devices

7. Insulin Delivery Devices Market, By End User

7.1 Patients/Homecare

7.2 Hospitals and Clinics

8. Geographical Analysis

8.1. Introduction

8.2. North America

       10.2.1. U.S.

       10.2.2. Canada

       10.2.3. Mexico

8.3. Europe

       8.3.1. U.K.

       8.3.2. Germany

       8.3.3. Italy

       8.3.4. France

       8.3.5. RoE

8.4. Asia Pacific

       8.4.1. South Korea

       8.4.2. China

       8.4.3. Japan

       8.4.4. India

       8.4.5. RoAPAC

8.5. RoW

       8.5.1. Latin America

       8.5.2. Middle East and Africa

9. Company Profiles

(Business Overview, Financial Overview, Product write up, Recent Developments)

9.1 Becton, Dickinson and Company

9.2 Novo Nordisk A/S

9.3 Ypsomed Holding AG

9.4 Medtronic plc

9.5 Animas Corporation

9.6 Tandem Diabetes Care, Inc.

9.7 Sanofi

9.8 Biocon Ltd.

9.9 Eli Lilly and Company

9.10 Insulet Corporation

(A brief overview of 10 companies is also provided)

10. Competitive Analysis

10.1. Introduction

10.2. Market Positioning of Key Players

10.3 Competitive Strategies Adopted by Leading Players

        10.3.1. Investments & Expansions

        10.3.2. New Product Launches

        10.3.3. Mergers & Acquisitions

        10.3.4. Agreements, Joint Ventures, and Partnerships

11. Appendix

11.1. Questionnaire

11.2. Available Customizations 

11.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)

Summary

No Content Available.

PURCHASE OPTIONS

ASK FOR SPECIAL PRICING

Related Reports